A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients
We previously reported that a second dose of BNT162b2 was safe and effective for allogeneic hematopoietic stem cell transplantation (HSCT) patients. Here, we investigated the safety and efficacy of a third dose of COVID-19 mRNA vaccine in allogeneic HSCT patients. Antibody titers against the S1 spik...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/11/1830 |
| _version_ | 1797466316988219392 |
|---|---|
| author | Marika Watanabe Kimikazu Yakushijin Yohei Funakoshi Goh Ohji Hiroya Ichikawa Hironori Sakai Wataru Hojo Miki Saeki Yuri Hirakawa Sakuya Matsumoto Rina Sakai Shigeki Nagao Akihito Kitao Yoshiharu Miyata Taiji Koyama Yasuyuki Saito Shinichiro Kawamoto Katsuya Yamamoto Mitsuhiro Ito Tohru Murayama Hiroshi Matsuoka Hironobu Minami |
| author_facet | Marika Watanabe Kimikazu Yakushijin Yohei Funakoshi Goh Ohji Hiroya Ichikawa Hironori Sakai Wataru Hojo Miki Saeki Yuri Hirakawa Sakuya Matsumoto Rina Sakai Shigeki Nagao Akihito Kitao Yoshiharu Miyata Taiji Koyama Yasuyuki Saito Shinichiro Kawamoto Katsuya Yamamoto Mitsuhiro Ito Tohru Murayama Hiroshi Matsuoka Hironobu Minami |
| author_sort | Marika Watanabe |
| collection | DOAJ |
| description | We previously reported that a second dose of BNT162b2 was safe and effective for allogeneic hematopoietic stem cell transplantation (HSCT) patients. Here, we investigated the safety and efficacy of a third dose of COVID-19 mRNA vaccine in allogeneic HSCT patients. Antibody titers against the S1 spike protein were measured using the QuaResearch COVID-19 Human IgM IgG ELISA kit. The previous study included 25 allogeneic HSCT patients who received two doses of BNT162b2. Following the exclusion of three patients because of the development of COVID-19 (<i>n</i> = 2) and loss to follow-up (<i>n</i> = 1), the study evaluated 22 allogeneic HSCT patients who received a third dose of COVID-19 mRNA vaccine (BNT162b2 [<i>n</i> = 15] and mRNA-1273 [<i>n</i> = 7]). Median age at the time of the first vaccination was 56 (range, 23–71) years. Five patients were receiving immunosuppressants at the third vaccination, namely calcineurin inhibitors (CI) alone (<i>n</i> = 1), steroids alone (<i>n</i> = 2), or CI combined with steroids (<i>n</i> = 2). Twenty-one patients (95%) seroconverted after the third dose. None of our patients had serious adverse events, new-onset graft-versus-host disease (GVHD), or GVHD exacerbation after vaccination. A third dose of the BNT162b2 and mRNA-1273 COVID-19 vaccines was safe and effective for allogeneic HSCT patients. |
| first_indexed | 2024-03-09T18:35:11Z |
| format | Article |
| id | doaj.art-5a227181112b4ce698897b6215a8aae4 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T18:35:11Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-5a227181112b4ce698897b6215a8aae42023-11-24T07:13:21ZengMDPI AGVaccines2076-393X2022-10-011011183010.3390/vaccines10111830A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation PatientsMarika Watanabe0Kimikazu Yakushijin1Yohei Funakoshi2Goh Ohji3Hiroya Ichikawa4Hironori Sakai5Wataru Hojo6Miki Saeki7Yuri Hirakawa8Sakuya Matsumoto9Rina Sakai10Shigeki Nagao11Akihito Kitao12Yoshiharu Miyata13Taiji Koyama14Yasuyuki Saito15Shinichiro Kawamoto16Katsuya Yamamoto17Mitsuhiro Ito18Tohru Murayama19Hiroshi Matsuoka20Hironobu Minami21Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital Graduate School of Medicine, Kobe 650-0017, JapanDivision of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital Graduate School of Medicine, Kobe 650-0017, JapanDivision of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital Graduate School of Medicine, Kobe 650-0017, JapanDivision of Infectious Disease Therapeutics, Department of Microbiology and Infectious Diseases, Kobe University Graduate School of Medicine, Kobe 650-0017, JapanDivision of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital Graduate School of Medicine, Kobe 650-0017, JapanR&D, Cellspect Co., Ltd., Morioka 020-0857, JapanR&D, Cellspect Co., Ltd., Morioka 020-0857, JapanDivision of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital Graduate School of Medicine, Kobe 650-0017, JapanDivision of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital Graduate School of Medicine, Kobe 650-0017, JapanDivision of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital Graduate School of Medicine, Kobe 650-0017, JapanDivision of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital Graduate School of Medicine, Kobe 650-0017, JapanDivision of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital Graduate School of Medicine, Kobe 650-0017, JapanDivision of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital Graduate School of Medicine, Kobe 650-0017, JapanBioResource Center, Kobe University Hospital, Kobe 650-0047, JapanDivision of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital Graduate School of Medicine, Kobe 650-0017, JapanDivision of Molecular and Cellular Signaling, Kobe University Graduate School of Medicine, Kobe 650-0017, JapanDivision of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital Graduate School of Medicine, Kobe 650-0017, JapanDivision of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital Graduate School of Medicine, Kobe 650-0017, JapanDivision of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital Graduate School of Medicine, Kobe 650-0017, JapanDivision of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital Graduate School of Medicine, Kobe 650-0017, JapanBioResource Center, Kobe University Hospital, Kobe 650-0047, JapanDivision of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital Graduate School of Medicine, Kobe 650-0017, JapanWe previously reported that a second dose of BNT162b2 was safe and effective for allogeneic hematopoietic stem cell transplantation (HSCT) patients. Here, we investigated the safety and efficacy of a third dose of COVID-19 mRNA vaccine in allogeneic HSCT patients. Antibody titers against the S1 spike protein were measured using the QuaResearch COVID-19 Human IgM IgG ELISA kit. The previous study included 25 allogeneic HSCT patients who received two doses of BNT162b2. Following the exclusion of three patients because of the development of COVID-19 (<i>n</i> = 2) and loss to follow-up (<i>n</i> = 1), the study evaluated 22 allogeneic HSCT patients who received a third dose of COVID-19 mRNA vaccine (BNT162b2 [<i>n</i> = 15] and mRNA-1273 [<i>n</i> = 7]). Median age at the time of the first vaccination was 56 (range, 23–71) years. Five patients were receiving immunosuppressants at the third vaccination, namely calcineurin inhibitors (CI) alone (<i>n</i> = 1), steroids alone (<i>n</i> = 2), or CI combined with steroids (<i>n</i> = 2). Twenty-one patients (95%) seroconverted after the third dose. None of our patients had serious adverse events, new-onset graft-versus-host disease (GVHD), or GVHD exacerbation after vaccination. A third dose of the BNT162b2 and mRNA-1273 COVID-19 vaccines was safe and effective for allogeneic HSCT patients.https://www.mdpi.com/2076-393X/10/11/1830SARS-CoV-2 vaccinationallogeneic hematopoietic stem cell transplantationBNT162b2mRNA-1273COVID-19vaccination |
| spellingShingle | Marika Watanabe Kimikazu Yakushijin Yohei Funakoshi Goh Ohji Hiroya Ichikawa Hironori Sakai Wataru Hojo Miki Saeki Yuri Hirakawa Sakuya Matsumoto Rina Sakai Shigeki Nagao Akihito Kitao Yoshiharu Miyata Taiji Koyama Yasuyuki Saito Shinichiro Kawamoto Katsuya Yamamoto Mitsuhiro Ito Tohru Murayama Hiroshi Matsuoka Hironobu Minami A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients Vaccines SARS-CoV-2 vaccination allogeneic hematopoietic stem cell transplantation BNT162b2 mRNA-1273 COVID-19 vaccination |
| title | A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients |
| title_full | A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients |
| title_fullStr | A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients |
| title_full_unstemmed | A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients |
| title_short | A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients |
| title_sort | third dose covid 19 vaccination in allogeneic hematopoietic stem cell transplantation patients |
| topic | SARS-CoV-2 vaccination allogeneic hematopoietic stem cell transplantation BNT162b2 mRNA-1273 COVID-19 vaccination |
| url | https://www.mdpi.com/2076-393X/10/11/1830 |
| work_keys_str_mv | AT marikawatanabe athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT kimikazuyakushijin athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT yoheifunakoshi athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT gohohji athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT hiroyaichikawa athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT hironorisakai athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT wataruhojo athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT mikisaeki athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT yurihirakawa athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT sakuyamatsumoto athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT rinasakai athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT shigekinagao athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT akihitokitao athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT yoshiharumiyata athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT taijikoyama athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT yasuyukisaito athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT shinichirokawamoto athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT katsuyayamamoto athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT mitsuhiroito athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT tohrumurayama athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT hiroshimatsuoka athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT hironobuminami athirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT marikawatanabe thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT kimikazuyakushijin thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT yoheifunakoshi thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT gohohji thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT hiroyaichikawa thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT hironorisakai thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT wataruhojo thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT mikisaeki thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT yurihirakawa thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT sakuyamatsumoto thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT rinasakai thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT shigekinagao thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT akihitokitao thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT yoshiharumiyata thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT taijikoyama thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT yasuyukisaito thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT shinichirokawamoto thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT katsuyayamamoto thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT mitsuhiroito thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT tohrumurayama thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT hiroshimatsuoka thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients AT hironobuminami thirddosecovid19vaccinationinallogeneichematopoieticstemcelltransplantationpatients |